YARDLEY, Pa., Oct. 2, 2012 /PRNewswire/ -- OptiNose US Inc. today announced results of a study testing delivery of the migraine medicine sumatriptan with a novel device using OptiNose breath powered ...
July 7, 2010 (Los Angeles, California) — Patients with migraine who have not experienced relief with sumatriptan may benefit from another 5-hydroxytryptamine receptor agonist, report researchers ...
Triptans are effective medicines used to treat migraine headaches. They significantly reduce pain within two hours for most people. Complete relief is less common, but the likelihood may be greater if ...
Jerusalem The Food and Drug Administration has approved Teva Pharmaceutical Industries’ generic version of GlaxoSmithKline’s Imitrex, Teva announced Wednesday. Teva’s sumatriptan tablets will be ...
This prevalence stands in contrast to the limited research that addresses prevention or treatment of postdischarge headache recurrence. Although dexamethasone, naproxen, and tryptamine-based drugs ...
Acute treatment of migraine with a combination tablet containing sumatriptan and naproxen has better efficacy than monotherapy with either drug alone, without increased adverse events Brandes et al.
Trigeminal neuralgia is typically treated with chronic therapy, but patients occasionally require treatment for acute pain. Now, subcutaneous sumatriptan (Imitrex) and intranasal lidocaine have each ...
Tosymra Nasal Spray 10 mg is a Proprietary Acute Migraine Treatment Approved Under the 505(b)2 Pathway Based on Bioequivalence to Imitrex (sumatriptan) Injection 4 mg GlaxoSmithKline Recently Notified ...
Sumatriptan (as succinate) 4mg/0.5mL, 6mg/0.5mL; for SC inj. Imitrex Injection is supplied as a clear, colorless to pale yellow, sterile, nonpyrogenic solution as either prefilled syringe and/or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results